Modality
Degrader
MOA
BCMA ADC
Target
FcRn
Pathway
PI3K/AKT
MCCSCLC
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
~Aug 2018
→ ~Nov 2019
Phase 2
~Feb 2020
→ ~May 2021
Phase 3
~Aug 2021
→ ~Nov 2022
NDA/BLA
Feb 2023
→ Nov 2026
NDA/BLACurrent
NCT04692985
2,035 pts·MCC
2023-02→2026-11·Not yet recruiting
2,035 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-11-288mo awayPh3 Readout· MCC
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2026-11-28 · 8mo away
MCC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04692985 | NDA/BLA | MCC | Not yet recr... | 2035 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| ITC-879 | Intra-Cellular | Approved | FcRn | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα |